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There is substantial evidence to link what we eat to the reduction of the risk of major chronic diseases and/or the improvement
of functions. Thus, it is important for public health agencies and the food industry to facilitate the consumption of foods with
particular health benefits by providing consumer products and messages based on scientific evidence. Although fragmentary advice is
available from a range of sources, there is a lack of comprehensive scientific guidelines for the design, conduct and reporting of
human intervention studies to evaluate the health benefits of foods. Such guidelines are needed both to support nutrition science in
general, and to facilitate the substantiation of health claims. In the present study, which presents the consensus view of an International
Life Sciences Institute Europe Expert Group that included senior scientists from academia and industry, the term ‘foods’ refers to foods,
dietary supplements and food constituents, but not to whole diets. The present study is based on an initial survey of published papers,
which identified the range and strengths and weaknesses of current methodologies, and was finalised following exchanges between
representatives from industry, academia and regulatory bodies. The major factors involved in the design, conduct and reporting of studies
are identified, summarised in a checklist table that is based on the Consolidated Standards of Reporting Trials guidelines, and elaborated
and discussed in the text.
There is substantial evidence linking dietary factors to the
primary and secondary prevention of major chronic diseases
such as heart disease, diabetes and certain cancers(1–3), as
well as the improvement of functions, for example muscle
function or immune response(4,5). Thus, it is important for
public health agencies and the food industry to be aware of
these links and to provide messages and products that will
facilitate the consumption of healthy diets by consumers.
However, it is important that these messages and products
are supported by good scientific evidence.
The aim of the present study is to provide guidelines for
the design, conduct and reporting of human intervention
studies. These guidelines should assist with studies designed
to support nutrition science in a broad sense, and also aim
to substantiate health claims for foods. In the present study,
the term ‘foods’ is used to mean foods, dietary supplements
and food constituents, but does not cover whole diets.
These guidelines, which are the consensus view of an
International Life Sciences Institute Europe Expert Group,
were finalised following exchanges between representatives
from industry, academia and regulatory bodies(6). The
Expert Group carried out an initial survey of relevant research
papers published within pre-defined periods in two leading
peer-reviewed journals (Am J Clin Nutr; Eur J Nutr). This
database was subsequently augmented with selected research
papers, to provide examples not present in the initial selec-
tion. This survey facilitated the identification of the range,
and the perceived strengths and weaknesses of currently
reported methodologies, and these guidelines cite relevant
selected papers as examples of current practice.
The major factors involved in the design, conduct and
reporting of studies are identified in Table 1, which uses a
similar structure to that in the Consolidated Standards of
Reporting Trials (CONSORT) checklist for medical trials(7).
These factors are discussed in the text under the same main
headings used in Table 1.
Summary of existing guidelines
Although earlier guidelines exist(8), newer guidelines are
emerging in response to legal requirements(9). These guide-
lines include those aimed at particular products and health
benefits(10–12). However, there is a lack of a comprehensive
description on how to perform human nutrition intervention
studies in general, and particularly for the evaluation and sub-
stantiation of health claims on foods. Besides the ‘PASSCLAIM
(Process for the Assessment of Scientific Support for Claims on
Foods) Consensus Criteria’(13), which so far is the most con-
clusive summary, various collections of advice exist, which
are given fragmentarily in legal regulations or guidance
reports from international and national authorities or organis-
ations. These are outlined below.
European Food Safety Authority Scientific and Technical
Guidance(14) and the ‘Application Rules on Health Claims’ in
commission Regulation EC 353/2008(15) provide only minor
information on the conduct of human intervention studies.
Within Europe, additional information is available from the
Joint Health Claims Initiative(16), where some criteria on the
validity of human studies are listed. The ‘US Food and Drug
Administration Guidance for Industry’ (2009)(17) gives a
broad description on human intervention studies in a question
and answer style, which guides through relevant human
intervention issues. Important aspects for claim evaluation
can also be drawn from the updated ‘Health Canada Guidance
Document’ (2009)(18). The varying approaches to health claim
evaluation in Europe, the USA, Canada, Australia and New
Zealand, China and Japan have quite recently been reviewed
in a supplement issue of J Nutr (19). Additionally, the
‘FAO/WHO Codex Alimentarius Commission’ (2008)(20) gives
basic criteria for health claim evaluation. However, a concise
summary of evaluation criteria focusing on the conduct of
human intervention studies is not currently available. An
attempt in this direction may be the ‘Nutrition, Health
and Related Claims Consultation Paper (Proposal P293, to
be finalized by late 2011)’(21) by ‘Food Standards Australia
New Zealand’, which may provide details on the evaluation
and substantiation requirements for health claims.
Factors to be considered in the design, conduct and
reporting of human intervention studies
Study hypothesis
The primary hypothesis to be tested will directly influence all
other aspects of the study, including the study design and
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Table 1. Checklist: factors to be considered, and recommendations for best practice when designing, conducting and reporting human intervention studies to evaluate the health benefits of foods
Phase Factors to consider Recommendations for design and conduct Recommendations for reporting
Design Hypothesis Clear hypothesis Explicitly state hypothesis, link to primary outcome measures
Study design Appropriate design Clearly describe, with rationale
Duration Appropriate to design, intervention and outcome measures Clearly describe, with rationale
Intervention Test and control products suitably matched Describe test and control products in detail, with rationale
Amount Appropriate to outcome measures and to practical usage Clearly describe, with rationale
Outcome assessment Define primary outcomes and methods of measurement Clearly describe how and when assessed
and link to hypothesis
Define all secondary outcomes and methods of measurement Clearly describe how and when assessed
Eligibility criteria Define all eligibility criteria Describe criteria using objective, quantitative descriptors
where possible
Statistical considerations
Randomisation Use randomised design where possible and ensure appropriate
method for allocation sequence generation and concealment
Clearly describe randomised design and the methods used
for randomisation, sequence generation and concealment
Blinding Ensure double blinding if feasible, single blinding if not Describe how blinding was achieved (who was blinded
and how), report success rate
Size of study Conduct power calculation based on primary outcome measures Include all elements of power calculation
Conduct Study protocol
Ethical approval and trial registration Obtain full ethical approval, register trial,
comply with the Declaration of Helsinki
Give details of research ethics authority and approval number,
and database and registration number
Recruitment Define recruitment strategy and process,
including settings and dates
Explicitly describe strategy, provide participant flow diagram
Data collection
Background diet and
monitoring change
Select suitable methods to collect and analyse data Describe assessment and analysis methods, report descriptive
data on background diet and changes for all components
that may be relevant by allocated intervention group
Background health status and lifestyle,
and monitoring changes
Define relevant measures, select suitable methods of assessment Justify relevant measures, describe assessment methods,
and report relevant factors and changes by allocated
intervention group
Unintended effects Devise strategy and methods to capture data Report methods to assess unintended effects and report by
allocated intervention group
Adverse events Have mechanisms in place to record and
respond to adverse events
Clearly define and report all adverse events by allocated
intervention group
Compliance Define acceptable levels of compliance, use appropriate strategies
to maximise compliance, select and use rigorous but feasible
methods for assessment of compliance
Report methods used to measure and maximise compliance,
report compliance rates numerically and by allocated
intervention groups
Analysis and
interpretation
Statistical analysis Devise appropriate analysis methods, based on study
design and outcome measures
Describe distribution of data, present descriptive
characteristics by allocated intervention group, present
hypothesis tests for comparing allocated intervention
groups, make clear distinction between primary
v. secondary endpoint analyses, state whether analysis
ITT or PP
Discussion and interpretation Consider study limitations and generalisability of findings Discussion of limitations and generalisability of study findings
Conclusion Relate directly to hypothesis, study design, test product
and study participants
Clear statement of conclusion
ITT, intention to treat; PP, per protocol.
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duration, the eligibility criteria, the amount of the test product
and the nature of the control. The hypothesis should be based
on a thorough review of the available evidence. The primary
outcome measure should be clearly defined and relate to
the hypothesis.
Current practice. The review of current practice showed
that only a minority of the papers mentioned the term ‘hypoth-
esis’, with the majority framing the research question as ‘aims’,
‘objectives’ or ‘purposes’. While hypotheses can sometimes be
inferred from aims or objectives, this is not always the case
and therefore it is recommended that studies have a clearly
stated hypothesis.
Study design
Human nutrition intervention studies test hypotheses that
have been formulated based on prior knowledge. Prior
knowledge will include data from other human intervention
studies, and also epidemiological, animal and in vitro studies.
Where possible, all the available evidence should be reviewed
systematically(22) for efficacy, and include an assessment of
safety and potential risks.
Exploratory studies generally have a number of aims. These
may include evaluations of food matrix issues and the amount
to be consumed, and can also provide data on the variability
and time scale of outcome responses and the size of the
effect on outcomes responses, which can be used for power
calculations in subsequent studies.
Once these early studies have been completed, studies with
greater rigour will test the hypothesis that the product will
alter the expected outcome measures. Usually, a series of
studies will be conducted, with later studies extending the
work as the evidence accrues. Examples include increasing
the range of populations studied, using new and/or longer-
term outcome measures, assessing the minimum effective
amount to be consumed and evaluating different forms of
presentation or delivery of the test product.
The following three basic study designs are encountered:
single-arm studies; cross-over studies; parallel studies. Early
exploratory studies tend to be single arm with no control
group, and these can be a cost- and time-effective way of
assessing potential effects, but usually only as a forerunner
to controlled studies. These studies add to the totality of evi-
dence but cannot alone determine the effect of intervention.
In controlled studies, in addition to a group of participants
receiving the active nutrition intervention, there will be
another group that will act as a control. The outcome for
this latter group provides a suitable comparator, as it is gener-
ally inappropriate to assume that changes observed in the
group receiving the active intervention during the study are
necessarily entirely attributable to that particular intervention;
other factors may be responsible for them. For example, the
knowledge that a participant is receiving an active interven-
tion may alter their responses, particularly when dealing
with more subjective outcomes such as quality of life scales.
In parallel-group designs, each participant receives only
one of the nutrition interventions (product A or B, active inter-
vention or control) under study. Comparisons between groups
must therefore be made on a between-participant basis.
However, in some studies, it may be feasible to use a different
design in which participants receive more than one interven-
tion. In studies using cross-over designs, participants receive
all interventions under comparison, and the design specifies
the order of interventions. This has the advantage that
comparisons between interventions can be made on a
within-participant basis with a consequent improvement in
precision of the comparisons and therefore power of the
study. In such designs, participants act as their own controls.
In a cross-over design for two interventions, the participants
are allocated to two groups which receive interventions in a
different order. Assessments are performed at the end of
each intervention period, although in some cross-over studies,
baseline measurements may also be taken at the start of each
intervention period. Depending on the intervention and out-
come measure, a washout period may be required between
intervention periods to avoid contamination or carry-over
effects. Also a run-in period may be desirable in advance to
minimise order effects. During this period, participants may
be asked to avoid certain foods. A Latin square design may
be used, where appropriate, to extend cross-over studies to
more than two interventions. However, any increase in
study length may increase participant dropout rate.
For studies that require longer-term interventions, parallel
studies are usually preferred, because of their shorter overall
time frame. Furthermore, parallel studies are essential where
a washout period may be ineffective at returning outcome
measures to baseline, for example in certain tests of cognitive
function. Parallel studies are also required where intentionally
returning to baseline may be unethical, for example if body
weight or bone mineral density may be affected. Parallel
studies are least suited to outcomes that show large inter-
participant variation. Cross-over studies are favoured where
participant availability may be restricted, and in very
short-term studies, for example postprandial studies to
evaluate glycaemic responses, or satiety and energy intakes.
However, they are adversely affected by dropouts and necessi-
tate a more complex analysis methodology. The choice of
study design will depend on these considerations, but also
the availability of time and other resources, and the potential
roles of confounding factors such as seasonal variations.
Other less commonly used types of study include (1) the
factorial design (in which participants are allocated to all
possible combinations of two or more interventions and
which permits the evaluation of intervention interactions)
and (2) the cluster randomised design (in which the unit of
randomisation is not the individual but a cluster of individuals
defined, for example, by family, school class or primary care
group). Further guidance on these designs is available in
statistical texts on clinical trials(23–27).
Study duration
The study duration should be sufficient to allow changes in
the primary outcome measure. Thus, the duration will be
informed by data from exploratory studies, from knowledge
of the underlying physiology and biochemistry, particularly
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the rates of turnover of relevant tissues such as erythrocytes,
or from similar studies that have used the same outcomes. It
also relates to the envisaged claim or hypothesis, which may
focus on an acute effect (e.g. glycaemic response or increased
alertness) v. a longer-term health outcome. Thus, no absolute
guidelines can be given on study duration. However, research-
ers should aim to use the minimum feasible duration for
ethical reasons, to conserve resources and to avoid participant
fatigue leading to non-compliance or withdrawal. In some
cases, post-study follow-up measures are desirable to evaluate
persistence or other longer-term effects.
Test and control product
Test product. The test product will be the supplement, ingre-
dient or food under investigation. Consideration must be
given, however to the intended use of the test product, and
the study design should take this into account. For example,
if it is intended that the test product be consumed as part of
a mixed meal, consumed once a day, then the study design
should be testing that pattern of consumption, and details of
frequency and timing of ingestion reported.
Amount consumed. The amount of the test product to be
consumed will depend on a number of factors. These include
evaluation of data from all previous studies, and consideration
of the underlying physiology and of issues related to the food
matrix, palatability and bioavailability. However, the amount
to be consumed should be close to that intended for practical
use. Furthermore, it is important to give relevant documentary
evidence of the amount of the test product or the component
with putative activity that is provided.
Control product. The control is a product that does not
provide the component that is being tested, and this must
also be analytically documented. The control should be
matched for sensory characteristics and taken in the same
way as the test product. A control is relatively easy to achieve
in supplementation studies using pills or similar preparations,
but in studies of foods, it is more difficult to develop a control
product identical to the test product but which does not
contain the component(s) under study. Blinding may not be
possible for many foods where the test product is easily
identifiable by the researchers, as may be the case with
some minimally processed foods such as fruits or vegetables,
and some manufactured consumer foods such as cereal pro-
ducts. However, some degree of blinding may be possible
by the use of suitable packaging that conceals products from
the researchers and other study participants.
Success in attaining an ideal control is likely to vary depend-
ing on the type of ingredient or product under test. Ideal
controls for different product types are considered below.
Supplements (pills, powders, liquids of small volume).
The provision of high-quality control products should be rela-
tively easy. Pills should be of identical size, shape, colour and
appearance. Ensuring identical internal colour, appearance,
mouthfeel and taste for all supplements is also desirable.
Food ingredients (e.g. fibres, starches, proteins, fats).
These can be evaluated in the form of supplements (see the
previous section) or incorporated into suitable consumer
foods (see the next section). The potential effects of inter-
action with other food components, and/or potential effects
of processing (e.g. degree of loss or modification, effects on
bioavailability) must be considered.
Manufactured consumer foods (e.g. cereal products, juices,
prepared dishes, yogurts). Test and control foods should be
similar in energy content and in physical characteristics (gross
morphology, appearance, volume and texture) and sensory
qualities (mouthfeel, taste, palatability and breakdown
characteristics in the mouth). If identical products cannot be
produced, then it is possible that compositional, physical or
sensory differences in the test and control products, unrelated
to the factor under test, may exert confounding physiological
or behavioural effects unrelated to the factor under test, and
will also make effective blinding difficult. In these circum-
stances, appropriate physiological or behavioural responses
should be monitored and compared for the test and control
products.
Minimally processed foods (e.g. fresh fruit, vegetables,
nuts, eggs, grains). The formulation of control products is
impossible if the aim is to use a single foodstuff, such as
fruit or nuts. If the control arm only involves the provision
of no test product or a smaller number of portions of the
test product, then this may have effects on other aspects of
diet and behaviour.
Outcome measures
All intervention studies will assess outcome measures, and
will compare these between intervention test product and
control groups, if a control group features in the study
design. Most studies will have a range of outcome measures,
but the study should be powered based on a pre-specified
primary outcome and the sample size calculated based on
that outcome (see the Size of study section). Similarly, if an
outcome is assessed at several time points over the course
of the study, either a single time point or a single summary
measure of results at several time points should be pre-
specified as the primary measure. All outcomes measures,
whether primary or secondary, should be stated and defined
in the study protocol.
It is essential that the outcome measure is of biological
relevance. In some cases, the outcome measure is clearly
relevant as it is a direct, objective measure of the intended
effect, for example body weight, or diagnosis of a disease or
muscle strength. Subjective measures are also used, such as
feelings of health, appetite or fatigue, and, in these cases, it
is important to use validated instruments if these are available.
When the effect cannot be measured directly, indirect or
surrogate factors such as biomarkers or risk factors are used
that reflect a functional, physiological or biochemical charac-
teristic associated with a function or a disease, or that predict
later development of the disease. Examples include glycated
Hb as an indicator of long-term hyperglycaemia and risk of
type 2 diabetes complications(28), plasma LDL-cholesterol as
a measure of CVD risk(29), bone mineral density as a measure
of osteoporosis risk(30), complex metabolomic or proteomic
profiles as markers of function and disease risk(31), and the
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presence of adenomatous colon polyps as an early indicator of
colon cancer(32). Most indirect outcome measures are chosen
because they reflect consensus guidelines or are commonly
used by experts in the area. However, very few markers
have been validated and recognised by expert consensus in
terms of their specificity, variability, limitations and applica-
bility to a range of population groups(13).
Methodological aspects. Efforts should be made to
standardise all outcome measure assessments and reduce
measurement error as far as possible (e.g. by standardising
measurement protocols, training observers and averaging sev-
eral measurements rather than using a single measurement),
especially if measurement errors are known to be large.
Analytical variability. Laboratory analytical methods
should be precise, accurate, sensitive and specific, and these
performance characteristics should be recorded in standard
operating procedures or similar quality record documents.
Intra-laboratory analytical variability should be minimised by
using automated equipment to analyse samples in duplicate
or triplicate, in batches that represent the range of interven-
tions, participants and sampling times, with suitable internal
and external standards and participation in quality assurance
programmes. Ideally, all samples from a study should be
analysed at the same time, and all samples from an individual
participant in one run, but this may be precluded by degra-
dation in storage, even at low temperatures. Inter-laboratory
analytical variability, which may be a factor in multi-centre
studies, should either be minimised by the sharing of
methods, standard operating procedures and calibration stan-
dards, or be overcome by centralisation of sample analysis.
Where appropriate, statistical analysis should be used to
account for any remaining inter-laboratory variation. Bio-
markers that have high methodological variability will often
require a higher number of participants.
Biological variability. Biological variability has a number
of underlying factors, and such variability is likely, in part,
to be genetically determined. Many biomarkers, similar to
most biological parameters, have circadian or seasonal vari-
ations. The basal value can also fluctuate due to biological
rhythms, such as the menstrual cycle. This variability may
introduce systematic bias into the results. Thus, it is important
to understand the factors underlying this variability for the
biomarkers, and to take samples or adapt the study design
accordingly.
Biologically meaningful changes. A study may show
a statistically significant change in a validated biomarker.
However, a statistically significant response of an outcome
measure to a nutrition intervention does not necessarily
mean that the intervention will be effective in terms of benefit
or risk reduction in target groups. Therefore, the size of
changes and whether these will be of biological, clinical or
public health significance must also be considered.
Selection of participants: eligibility criteria
Eligibility criteria are functional, physiological or clinical
characteristics or demographic variables used to define the
study population. Eligibility criteria may also include lifestyle
factors such as smoking habit or level of physical activity,
and dietary factors such as low fibre intakes, or the consump-
tion of restricted diets. Eligibility criteria can be presented as
inclusion and exclusion criteria. The criteria are likely to
include factors such as age, sex, health status, and underlying
physiological conditions or concurrent diseases.
Eligibility criteria should describe participants adequately,
so that the results can be appropriately interpreted in terms
of their generalisability. Eligibility criteria should be selected
with the target population for the test product, and the
hypothesis and outcome measures in mind. Inter-participant
variation may usefully be reduced by using stricter eligibility
criteria to select a more homogeneous set of participants for
study, but this also has the disadvantage of restricting the
target population and consequently limiting the generalisabil-
ity of findings. Children and women of childbearing age may
need to be excluded from studies of certain interventions with
developmental implications or teratogenic potential.
It is important to define eligibility criteria using objective,
quantitative descriptors wherever possible. For example,
many nutrition interventions use ‘apparently healthy’ partici-
pants. Health may be evaluated by using a questionnaire on
medical history and surgical events, or this may be extended
to a physical examination and screening of blood and
urine(33). ‘Health’ may just refer to the absence of diagnosed
disease, or refer to a specific aspect such as a healthy blood
pressure, and in such cases, the criteria can be very specific(34)
and may follow official guidelines. However, ‘apparently
healthy’ may also include a healthy lifestyle, which could be
assessed using questionnaires, for example, for physical
activity, dietary habits, smoking, alcohol and medication use.
Current practice. The majority of human intervention
studies report and define eligibility criteria to some extent.
However, most papers do not give all eligibility criteria, quantifi-
able ranges for these criteria or a clear rationale for these criteria,
and do not relate the criteria to the hypothesis being tested. In
addition, many studies mention ‘healthy’ as an inclusion cri-
terion without defining ‘health’ status. An example of good prac-
tice is Brink et al.(35), where inclusion and exclusion criteria are
described with quantifiable ranges for many of the criteria.
Statistical considerations
Randomisation. Randomisation is the allocation of interven-
tions to participants using some random process such as the
toss of a coin. Randomisation ensures that the investigator
does not influence the intervention to which a participant is
allocated. The main advantage of random allocation is that,
in the long run, it will produce study groups, which are com-
parable with respect to both known and unknown factors,
which could influence the outcome measure. Consequently,
any observed difference in the responses of the two inter-
vention groups is likely to be due to the effects of the
intervention. Randomisation helps to ensure that the compari-
son of interventions is fair (unbiased) and the statistical
analysis is valid.
To allocate individual participants to intervention groups,
random numbers (either from tables or generated by
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computer) can be used. However, it is advisable to ensure that
approximately equal numbers of participants are assigned to
each group by using a block randomisation, in which partici-
pants are divided into blocks within which equal numbers of
allocations to each intervention are made. To avoid any poss-
ible predictability of the allocations at the end of a block it is
advisable to vary the block size. It is often desirable to stratify
participants into subgroups defined by important variables
such as age, sex and ethnicity that could influence the
response to intervention. A restricted randomisation is then
conducted within each subgroup. Stratification will generally
result in more comparable study groups and can also reduce
variability in the response measure when incorporated in
the statistical analysis. Minimisation offers a more practicable
approach to stratification on multiple variables.
Concealment of the intervention allocations. The decision
to enrol a participant in a study could be influenced subcon-
sciously or otherwise by the knowledge of which intervention
the participant would receive if entered into the study.
A simple way to eliminate any possible bias of this sort is to
implement randomisation using sealed envelopes. The list of
random intervention allocations is concealed in sequentially
numbered opaque sealed envelopes. Only after a participant
has been enrolled in the study and consent obtained should
the seal be broken to reveal which intervention the participant
has been allocated.
Blinding. The assessment of study outcomes may be
influenced by knowledge of which intervention was received,
particularly for subjective outcomes. Such bias can be avoided
by using blinded assessment. If neither the assessor nor the
participant knows which intervention the participant received,
then the study is double blind. If the participant knows but
the assessor does not (or vice versa), then the study is single
blind. Blinding should also be carried through into laboratory
determinations and statistical analysis. The time of unblinding,
usually after the freezing of the database, should be documen-
ted in the study report and may be mentioned in the
publication.
Where possible, and particularly for food products, the
effectiveness of blinding should be assessed at the end of
the study and commented on in the study report. This can
be achieved by the use of a simple questionnaire asking par-
ticipants which product (test or control) they thought they
were consuming. Currently, this information is rarely reported.
Size of study. Estimation of the number of participants
required for the study is essential. Too small a study is likely
to fail to detect important differences between interventions,
while too large a study may needlessly waste resources and
be unethical. In certain circumstances, trials may be designed
for interim analysis as each participant’s result becomes
available (sequential design) or after pre-specified numbers
of participants’ results become available (group-sequential
designs)(23–27). These designs are ethically appealing because
they ensure that inferior interventions are quickly identified,
so minimising the numbers receiving them. However, even
when such early termination is feasible, it is not always advi-
sable since it can lead to intervention effects being estimated
with poor precision. Usual methods for sample size estimation
require specification of the magnitude of the smallest mean-
ingful difference in the outcome variable. The study must be
sufficiently large to have acceptable power to detect this
difference as statistically significant, and must take into
account possible non-compliance and the anticipated dropout
rate. Information about the degree of variability in the
outcome is also required and may come from previously pub-
lished or unpublished results, or from a pilot or exploratory
study specifically performed for the purpose. A multi-centre
study may be necessary if the study size is too large to be
performed in a single centre. Statisticians are key members
of research teams, and it is recommended they are involved
at an early stage, not only in study size calculation, but also
in planning the design of the study.
Ethical approval and study registration
Researchers should determine the appropriate local ethical
approval and research governance procedures required for
their study, and seek these approvals before the study com-
mences. While not all nutrition research may be classified as
medical research, it is recommended that researchers adhere
to the World Medical Association’s Declaration of Helsinki(36).
One of the recommendations of the Declaration of Helsinki is
that every clinical trial (including human nutrition intervention
studies) must be registered in a publicly accessible database
before recruitment of the first participant. Such registration,
with accompanying protocol details, is intended to reduce
the consequences of non-publication of studies (e.g. rep-
etition of negative studies), selective reporting of outcomes,
and of per-protocol rather than intention-to-treat analyses
(see the Statistical analysis section). The WHO(37) has stated
that ‘the registration of all interventional trials is a scientific,
ethical and moral responsibility’ while the International Com-
mittee of Medical Journal Editors have, from September 2004,
only considered trials for publication if they were registered
before enrolment of their first participant(38). The academic
view is that a priori trial registration is essential for ethical
research in human participants. For industry-based nutrition
studies, where the results may be commercially sensitive
or where intellectual property rights may be jeopardised, a
position similar to that in the pharmaceutical industry could
be adopted, whereby five items of protocol information are
kept hidden in a locked electronic depository that is publicly
inaccessible until the information is no longer deemed
commercially sensitive(39).
Recruitment and participant flow
The study protocol should state the methods by which partici-
pants will be recruited, and details of the recruitment process
should be carefully described, with details of participants
approached, screened, recruited and completing, and reasons
for non-recruitment (ineligibility, lack of willingness to partici-
pate) and non-completion noted. Informed consent should be
obtained. This information is best summarised in a participant
flow diagram when reporting the study(7).
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Data collection
Data should be collected using standardised case report forms.
Participants should be assigned a unique study number at the
start of the study, and data held under that study number, i.e.
there should be no participant identifiable information held by
the researchers, other than a single sheet where the study
number is linked to the participant contact details. All data,
both paper and computer-based, should be kept securely
and all data collection conducted in line with the required
local regulations.
Background diet and change in diet during intervention.
The nature of the participants’ background diet may be one
of the eligibility criteria. However, it is important, regardless
of eligibility criteria, and particularly in longer-term studies,
to collect background dietary information in order to charac-
terise the habitual diet of the participants in terms of foods
and diet composition. Diet should also be assessed during
longer-term interventions, in order to detect any potentially
confounding changes that may occur. A number of method-
ologies are available for these dietary assessments (e.g. FFQ,
food diary, diet history(40)), However, dietary intake assess-
ment is subject to misreporting, and reported energy intakes
should be compared with the estimated energy requirements
of participants, particularly if these assessments are used for
monitoring compliance.
Background health status and lifestyle, and changes in
health status and lifestyle during intervention. In addition
to their possible roles as eligibility criteria, it is also important
to characterise the study population in terms of demographic
background, health status and lifestyle behaviours, in order to
allow suitable interpretation and generalisation of the results.
Examples include age, sex, level of medication use, physical
activity and smoking habit. The monitoring of health status
and lifestyle behaviours should also be carried out in the
course of longer-term studies to assess potential between-
group differences, which may confound outcome measures.
This is particularly important in studies where it is not possible
to use closely matched test and control products.
Unintended effects. Aside from formal adverse events
(AE), which are discussed below, in nutrition studies, there
may be other unintended effects (to use recent CONSORT(7)
terminology). Unintended effects arising during nutrition
studies are likely to be restricted to, for example, mild
nausea or minor gastrointestinal discomfort as a result of
changes in dietary pattern or consumption of unfamiliar or
blinded products.
The recording of these unintended effects is desirable in
human nutrition interventions, providing data on the tolerabil-
ity of the product and enabling the compilation of a dossier
for future reference. Questionnaires should be used to provide
quantifiable data, using standardised formats where available,
for example to assess gastrointestinal effects such as bloating
or flatulence. Data should be collected at baseline and at suit-
able intervals during the study to assess onset and time course.
Time, intervention and group effects should be tested statisti-
cally and, if significant, potential influence on compliance,
withdrawal and outcome measures should be considered.
Adverse events. An AE is any untoward medical occur-
rence or undesirable clinical experience in a participant in a
clinical trial, whether or not considered related to the interven-
tion. Recording AE is of major importance in pharmaceutical
studies, allowing a risk–benefit analysis. Hence, there is an
abundance of guidelines for the management of AE in
the clinical study setting (e.g. European Medicines Agency;
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human
Use; US Department of Health and Human Services, Food
and Drug Administration)(41–43). There are no guidelines for
nutrition intervention studies, given that these studies involve
testing foods, supplements or ingredients in participants who
are usually apparently healthy. However, the formal recording
of AE is required for good practice in nutrition research.
Any serious or unexpected AE that are encountered,
whether or not they appear related to the intervention,
should be reported immediately to the principal investigator,
the research ethics committee, the sponsor and relevant regu-
latory bodies in order to ensure appropriate management.
Compliance
Any deviations from protocol can affect the validity and rel-
evance of an intervention study. Low levels of participant
compliance in nutrition studies decrease the power to detect
effects, and cause the reporting of false negative findings,
and ultimately a lack of evidence to support a potentially ben-
eficial effect. Poor compliance in a particular subgroup will
also reduce the generalisability of results. When compliance
is very different between allocated groups, this may be
because acceptability of the interventions differs. Therefore,
a nutrition intervention study should aim to have measures
in place to maximise and assess compliance.
Methods to measure and maximise compliance. The
choice of compliance assessment methods will depend on
study design, duration and intervention type. In acute or post-
prandial studies, the intervention is usually consumed only
once under supervision and thus, compliance is not usually
an issue. However, maintaining compliance throughout
longer-term studies is very important. Informing participants
that compliance will be measured by one of the methods
below is likely, in itself, to improve adherence to the dietary
intervention.
Complete provision of intervention, consumed under
supervision. This will maximise compliance, but requires
access to a metabolic suite or equivalent, and there will be
resource implications. The suitability of this approach is
likely to depend on the duration of the intervention.
Complete provision of intervention, with the return of
unconsumed items. The return of unconsumed items is
often used, but there can be no certainty that the participant
has actually consumed all unreturned items.
Assessment of biomarkers in biological samples. Where
possible, an independent and objective measure of compli-
ance should be used, for example assessment of Se in serum
or fatty acid composition of erythrocyte membranes(10).
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Using dietary records. Weighed food intakes, food diaries,
food checklists and dietary recall methods, including diet his-
tories, can be used. An inherent weakness of self-reported
dietary intake data is the prevalence of socially desirable
responding, where participants tend to under-report overall
dietary intake and to over-report intakes of the intervention
foods, and ‘healthy’ foods in general. Dietary records can use-
fully augment objective biological markers. If valid biomarkers
of exposure do not exist, it is important to try to ensure that
intakes are reliably reported.
A combination of the above. As no single method of
assessing compliance is completely infallible, a combination
of methods may be required.
In addition to the compliance assessment methods above,
maintaining close, regular contact with participants is key to
achieving good compliance, allowing any issues to be ident-
ified and dealt with at an early stage.
Acceptable levels of compliance. Acceptable levels of
compliance for human nutrition studies have rarely been
stated, and are difficult to comment on definitively. See later
section on Statistical analysis for discussion of how compli-
ance will affect statistical analysis. A decision on the statistical
analysis approach will be partly influenced by whether studies
are designed as tests of efficacy (biological effect) or effective-
ness (potential to modify outcome in real-life situation), as the
former studies will be more focused on maximising compli-
ance. Making a decision on an acceptable level of compliance
relies on an accurate, objective assessment of compliance as
detailed above. A priori decisions should be made regarding
the acceptable level of compliance for inclusion in a per-
protocol analysis.
Current practice. An acceptable level of compliance is
rarely reported quantitatively, with the extent of compliance
usually reported qualitatively. However, as an example of
good practice, Brink et al.(35) monitored compliance by a com-
bination of specially designed forms, return of unconsumed
foods, and assessment of both plasma and urine concen-
trations of isoflavones. These authors reported that the level
of compliance was high (94 %) and did not differ between
intervention groups. Plasma isoflavone concentrations
increased significantly in the active intervention groups.
Statistical analysis
There are a number of statistics books that cover the basics of
randomised intervention trial methodology and analysis(23–27).
It is good practice to have a statistical plan that specifies the
statistical methods to be used, the hypotheses to be tested
for both primary and secondary outcomes (including whether
one-sided or two-sided), and the significance level to be
employed.
Rationale for using statistical methodology. In common
with other research in medicine and the biological sciences,
differences between groups which the investigator wishes to
identify in a nutrition study are usually masked by several
types of variation (inter- and intra-participant variation,
measurement error, etc.), and strategies to minimise these
have been outlined earlier.
These sources of variation mean that there is a need for the
results of a study to be assessed objectively using appropriate
statistical methodology. This section describes the basic
statistical concepts necessary for the analysis of nutrition inter-
vention studies. Although tests of hypotheses play a key role
here, it is worth emphasising that the calculation of CI for
intervention effects can often be more informative.
In general, statistical techniques require an assumption that
the group under study may be considered to be a random
sample from a target population about which inferences are
to be made. In practice, there would be considerable practical
difficulties in mounting an intervention study on a truly
random sample from a target population, and usually a con-
venience sample such as a group of healthy volunteers or
patients attending hospital outpatient clinic will be studied.
The investigator should be particularly cautious in any extra-
polation of findings beyond the population from which the
study sample was drawn. It is also worth emphasising that
statistical methods will only take account of sampling error
(i.e. variation arising from the process of sampling); they
cannot quantify the extent of biases attributable to non-
random sampling, particularly bias that may be introduced
through non-response.
Preliminary steps in data analysis. Before attempting any
formal statistical comparisons, it is important to visualise the
data with histograms and scatter diagrams to examine the
shapes of distributions, to check for outliers and to establish
the nature of any relationships between variables.
Suitable descriptive statistics should also be presented to
characterise the participants under study, and an indispensa-
ble step in a comparative study will be to construct a table of
participant characteristics by group. For quantitative variables,
this should include both measures of location and measures of
dispersion, typically the mean and standard deviation for
roughly symmetrically distributed variables or the median
and interquartile range for variables whose distribution is
heavily skewed. For categorical variables, both frequencies
and percentages should be included in this table. In an
adequately randomised study, it is not usually considered
necessary to perform statistical tests on these baseline group
characteristics since any differences observed between
groups must be due to chance.
Hypothesis tests for comparing groups. Along with the
study design, the scale of measurement of the response
variable is of fundamental importance in deciding which stat-
istical analysis techniques to use. The following provides a
brief description of statistical techniques suitable for simple
randomisation studies.
Parametric methods. For a study using a parallel-group
design and an interval-scale response variable (e.g. weight
or blood pressure), the independent-samples t test will be
used to compare two groups and one-way ANOVA to compare
three or more groups(23,25). For the two-period cross-over
study, a refinement of the paired t test, which takes account
of variability attributable to period effects, is typically
employed(44). If baseline values of a response variable are
available, then changes in the variable during the intervention
may be calculated and used in the analysis, although it can be
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more beneficial to analyse the final value of the response in an
ANCOVA with the initial value considered as the covariate.
For studies that take more than two serial measurements of
response variables, the derivation of a summary measure
such as a slope or area under the curve may permit the appli-
cation of straightforward statistical techniques and avoid more
complex methods for correlated responses(45). Intervention
effects, often expressed as means, or differences in means,
should be estimated along with their associated 95 % CI.
Non-parametric methods. For ordinal-scale outcomes,
non-parametric methods are typically employed with the
Mann–Whitney U test used to compare two groups and
Kruskal–Wallis one-way ANOVA of ranks to compare three
or more groups(23,25). These techniques may also be used
for analysing interval-scale response variables, which do not
satisfy the assumptions for the parametric methods. However,
these techniques focus on hypothesis testing, and confidence
limits associated with these techniques are not widely
available.
Contingency table methods. For nominal-scale (or unor-
dered categorical) outcome variables, the analysis is per-
formed using x 2 tests for contingency tables or Fisher’s
exact probability test where numbers are small. CI for pro-
portions, for differences in proportions, for OR or for risk
ratios may also be useful for characterising intervention
effects.
If information on covariates is available, then it may be
incorporated into a multiple regression analysis to improve
the precision of comparisons between interventions on an
interval-scale response. This technique may also be a useful
approach in adjusting for chance imbalances between the
intervention groups on factors relevant to the response.
Similarly, for a categorical response variable, logistic
regression analysis may be used.
The interpretation of analyses involving more than two
intervention groups may be complicated by the multiplicity
of statistical tests. If the aim of an analysis is restricted to
making only a small number of pre-specified comparisons
between groups as stated in the study protocol, then multiple
testing is less of an issue. However, tests of hypotheses other
than these (e.g. hypotheses formulated after looking at the
results) require a more conservative approach in the statistical
analysis to limit the risk of false positive findings. A similar
issue arises in the interpretation of tests on multiple response
variables. Ideally, investigators should nominate the primary
response variable in the study protocol. Other responses
may still be analysed but a stricter significance level may be
appropriate to safeguard against false positive findings.
A recent development in nutrition research has been to use
genomics, proteomics and metabolomics approaches as end-
points in nutrition intervention studies(31). The use of multiple
endpoints such as these raises some statistical issues. If the
multiple endpoints are independent, then a simple Bonferroni
correction is sufficient to control the risk of type 1 error with a
significance level set not at the a level but at the a/k level,
where k is the number of endpoints. An alternative approach,
which retains more power than the Bonferroni correction and
is more suited to microarray work, is to control the false
discovery rate, the expected proportion of false positives
among the results that are declared significant. For dependent
endpoints, comparisons may be performed by a permutation
test. This involves comparing the largest test statistic, not
with a standard distribution (such as the t distribution or x 2
distribution), but instead with its permutation distribution
obtained by calculating the largest test statistic in every poss-
ible relabelling of the groups (or at least in a very large
random sample of them).
Intention to treat or per protocol. An important issue in
the analysis is to decide how protocol deviations should be
handled in the analysis. Usually, the most relevant comparison
of interventions will include all randomised participants who
began the intervention, and the analysis will be conducted
on an ‘intention-to-treat’ principle. Once participants have
been randomised to intervention groups, all available results
are analysed in the groups to which they were allocated
regardless of whether or not the participants complied with
the intervention. In nutrition, interest sometimes focuses on
the subset of participants who showed good compliance
with the intervention (for a discussion of adequate levels of
compliance see the Compliance section) and a ‘per-protocol’
analysis may then be more relevant even though this
approach has a greater potential for introducing bias into
the comparison of interventions.
Discussion and interpretation
The interpretation of study findings, and discussion
section of a paper should include a consideration of the
study limitations, including any potential sources of bias
(e.g. imbalance in baseline characteristics), imprecision (in
outcome assessments) or an acknowledgement of the possi-
bility of statistically significant findings arising from multiple
comparisons. The generalisability of the study findings
should also be considered and limitations acknowledged.
Conclusions
The conclusions should be confirmed and justified by the
accompanying data. The conclusions should relate directly
to the hypothesis, to the test product at the amount consumed
and to the population included in the study. Conclusions
about secondary outcome measures should be stated as
such and interpreted appropriately.
Current practice. In practice, the hypothesis is often not
clearly stated, and this can make the validity of the con-
clusions difficult to judge. Sometimes, statistically significant
results are overemphasised when these were not the original
focus of the study design. Another issue that occurs frequently
is that findings of studies are generalised to broader popu-
lations than may be reasonable given the participant charac-
teristics. Inappropriate generalisation of study findings can
also occur in relation to the specific product and the amount
consumed, and to the duration of the study.
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Roles and responsibilities of the research team
The complex issues involved in potential conflicts of interest
and scientific bias, particularly when research funding may
come from the food industry, have recently been discussed(46).
Furthermore, many journals now require statements of the
roles and responsibilities of all members of the research
team, including the funders or sponsors, and declarations of
any potential conflicts of interest. We recommend that this
should be a standard practice.
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